FDA
-
-
-
-
-
-
-
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
-
-
-
-
-
-
-
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
-
-
-
-
-
-
-
BriaCell Therapeutics (BCTX) Highlights Additional Phase 3 Clinical Sites
-
-
-
322,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

